GYBYS(00874)

Search documents
北大核心期刊推荐白云山固肾定喘丸:提高临床有效率和用力肺活量方面表现最优
Nan Fang Nong Cun Bao· 2025-07-18 02:01
Core Viewpoint - A recent network meta-analysis published in a core journal indicates that Baiyunshan Gushen Dingchuan Wan shows superior efficacy in improving clinical effectiveness and forced vital capacity (FVC) for treating stable chronic obstructive pulmonary disease (COPD) [2][3][9]. Group 1: Research Findings - The study reviewed randomized controlled trials of oral traditional Chinese medicine for stable COPD treatment, utilizing a network meta-analysis approach [6][7]. - Results demonstrated that five types of oral traditional Chinese medicines significantly improved treatment outcomes with a high safety profile and minimal adverse reactions [8][9]. - Among the evaluated medicines, Gushen Dingchuan Wan exhibited the best performance in enhancing clinical effectiveness and FVC [9]. Group 2: Treatment Mechanism - Gushen Dingchuan Wan is formulated based on principles of warming the kidneys and lungs, and strengthening the spleen to alleviate symptoms in COPD patients with kidney and lung qi deficiency [10][13]. - The medicine aims to improve lung function and promote respiratory muscle recovery, thereby enhancing patient vitality and quality of life [11][14]. Group 3: Clinical Guidelines and Recommendations - Gushen Dingchuan Wan is included in several authoritative guidelines and consensus recommendations for COPD treatment, such as the "Clinical Application Guidelines for Integrated Traditional and Western Medicine in COPD (2024)" [16][17]. - Its inclusion in these guidelines supports its further application and promotion in the treatment of related diseases [20].
白云山鼻咽清毒颗粒研究成果首次亮相BOC/BOA大会
Guang Zhou Ri Bao· 2025-07-05 04:23
Core Viewpoint - The 2025 China Clinical Oncology Annual Progress Seminar (BOC) and Best of ASCO® 2025 China will be held on July 4-5, 2025, focusing on significant research findings from the ASCO annual meeting and enhancing the influence of Chinese scholars in the international arena [2]. Group 1: Clinical Research Findings - The IV phase clinical study led by Professor Liu Zhigang on "Baiyunshan Nasopharyngeal Detox Granules" demonstrated significant improvements in severe nasal secretion symptoms and reduced the incidence of severe oral mucositis in nasopharyngeal cancer patients undergoing radiotherapy, indicating a promising innovative treatment option [2]. - The study also reported improvements in symptoms such as throat pain and dryness, showcasing good safety profiles for the treatment [2]. Group 2: Background and Development - Radiotherapy remains the primary curative method for nasopharyngeal cancer, with approximately 90% of patients experiencing adverse reactions like radiation-induced oral mucositis, which severely impacts treatment outcomes and quality of life [3]. - Baiyunshan and Huang Zhong Medicine have invested in clinical research since 2022 to address radiation-induced damage in the nasopharyngeal area, with the project supported by prominent experts in the field [3][4]. - Baiyunshan Nasopharyngeal Detox Granules, developed in collaboration with Sun Yat-sen University Cancer Center and Guangzhou Pharmaceutical Group, is clinically used for chronic inflammation and increased secretion symptoms post-radiotherapy [4].
白云山(600332) - H股公告(证券变动月报表)

2025-07-02 09:00
FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年6月30日 狀態: 新提交 致:香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 (「本公司」) 呈交日期: 2025年7月2日 I. 法定/註冊股本變動 1. 股份分類 普通股 股份類別 H 於香港聯交所上市 (註1) 是 證券代號 (如上市) 00874 說明 香港聯交所上市 H 股 法定/註冊股份數目 面值 法定/註冊股本 上月底結存 219,900,000 RMB 1 RMB 219,900,000 增加 / 減少 (-) RMB 本月底結存 219,900,000 RMB 1 RMB 219,900,000 | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600332 | 說明 | | 於上海證券交易所 (「上交所」)上市之A股 | | | | | | | | 法定/ ...
白云山(600332) - H股公告(进展公告 向白云山生物增资)

2025-06-30 11:15
廣州白雲山醫藥集團股份有限公司 董事會 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性或完 整性亦不發表任何聲明,並明確表示,概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 關連交易進展公告 向白雲山生物增資 茲提述廣州白雲山醫藥集團股份有限公司(「本公司」)日期為2025年5月28日之公告(「該公告」),內容 有關向白雲山生物增資之關連交易。除另有界定外,本公告所用詞彙與該公告所界定者具有相同涵 義。 董事會欣然宣佈於2025年6月30日,本公司與廣藥創投基金、廣州老字號基金、廣藥產投基金、國資 併購基金、拜迪生物及白雲山生物訂立了增資協議,增資協議於同日正式生效。增資協議的主要條 款並無任何變更。增資協議的主要條款及本次增資詳情載於該公告。 本次增資完成後,本公司於白雲山生物的直接及間接持股比例維持不變,仍為50.00%。白雲山生物 仍為本公司之附屬公司,其財務業績繼續納入本公司之合併報表。 中國廣州,2025年6月30日 於本公告日,本公司董事會成員包括執行董事李小軍先生、程寧女士、程洪進先生、唐和平先生與 黎洪先生,及獨立非執 ...
白云山: 广州白云山医药集团股份有限公司第九届董事会第二十六次会议决议公告
Zheng Quan Zhi Xing· 2025-06-23 16:31
Group 1 - The board of directors of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. held its 26th meeting of the 9th session on June 23, 2025, with all 9 directors participating and voting [1][2] - The meeting approved the proposal to add new members to the specialized committees of the board, with a unanimous vote of 9 in favor, 0 against, and 0 abstentions [1] - The newly appointed members to the specialized committees include Mr. Li Xiaojun, Mr. Cheng Hongjin, and Mr. Tang Heping, effective from the date of the board's approval until the end of the current board's term [1][2] Group 2 - The composition of the Strategic Development and Investment Committee now includes Mr. Li Xiaojun as the chairperson and members Mr. Li Hong, Mr. Chen Yajin, and Ms. Sun Baoqing [1] - The Nomination and Remuneration Committee is chaired by Mr. Huang Min, with members including Mr. Chen Yajin, Ms. Sun Baoqing, and the newly added Mr. Cheng Hongjin [2] - The Budget Committee is chaired by Mr. Chen Yajin, with members including Ms. Cheng Ning, Mr. Huang Min, Mr. Huang Longde, and the newly added Mr. Tang Heping [2]
白云山能打造下一个金戈吗?
Xin Lang Cai Jing· 2025-06-10 06:01
Core Viewpoint - Baiyunshan has received approval for the registration of Tadalafil tablets, positioning it as a successor to its existing product, Jin Ge (Sildenafil) [1][3]. Group 1: Product Overview - Tadalafil is a PDE5 inhibitor similar to Sildenafil, primarily used for treating erectile dysfunction (ED) [1][3]. - Tadalafil has advantages over Sildenafil, including lower dosage, longer half-life, and less impact from high-fat meals and alcohol [3]. Group 2: Market Dynamics - The domestic market for Tadalafil has not performed as well as Sildenafil, facing intense competition and a dual market structure of hospital and retail sales [3][4]. - In 2024, Tadalafil's sales in public hospitals were only RMB 186 million, indicating a limited market size [7]. - The introduction of centralized procurement policies has compressed the market ceiling for Tadalafil in hospitals [4]. Group 3: Competitive Landscape - In 2024, Tadalafil's total sales in hospitals were RMB 142 million, with the original drug, Cialis, holding a 30.14% market share, while generic competitors have gained significant volume [7][11]. - The retail market for Tadalafil is much larger, with total sales of approximately RMB 2.906 billion in 2024, split between offline and online pharmacies [14]. - The online retail market is highly fragmented, with various brands competing for market share [20]. Group 4: Challenges and Future Outlook - Baiyunshan faces challenges in establishing Tadalafil as a blockbuster product due to the competitive landscape and lack of first-mover advantage [23]. - The company is also exploring other male health medications, such as Dapoxetine, but the overall market for these products is limited [24]. - Jin Ge's sales and revenue have declined in 2024, indicating potential saturation in its market [24][25].
广州白云山医药集团股份有限公司关于分公司收到药品注册证书的公告
Shang Hai Zheng Quan Bao· 2025-06-06 19:55
Group 1 - The company has received the drug registration certificate for Tadalafil tablets (2.5mg, 5mg) from the National Medical Products Administration [1][2] - Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor primarily used for treating erectile dysfunction (ED) [2] - The original manufacturer of Tadalafil is Eli Lilly, which received approvals in the EU and the US in November 2002 and November 2003, respectively, and in China in December 2004 [2] Group 2 - The company submitted the drug registration application for Tadalafil on January 2, 2024, and received acceptance on January 24, 2024 [2] - In 2024, the sales figures for Tadalafil tablets in Chinese public hospitals, urban pharmacies, and online pharmacies were approximately RMB 185.73 million, RMB 1.294 billion, and RMB 1.61182 billion, respectively [2] - The company has invested approximately RMB 2.54 million and RMB 4.30 million in the R&D of 2.5mg and 5mg Tadalafil tablets, respectively [3] Group 3 - The approval of Tadalafil tablets enhances the company's product offerings in the male medication sector, potentially increasing its market competitiveness [3] - The company plans to commence production in accordance with relevant requirements and market demand [3]
白云山: 广州白云山医药集团股份有限公司关于分公司收到药品注册证书的公告
Zheng Quan Zhi Xing· 2025-06-06 09:20
Core Viewpoint - The company has received the drug registration certificate for Tadalafil tablets (2.5mg, 5mg), enhancing its product offerings in the male medication market and improving its competitive position in this sector [1][2]. Drug Information - The drug's generic name is Tadalafil, with active ingredients being Tadalafil in tablet form, available in specifications of 2.5mg and 5mg [1]. - The registration classification is categorized as a Class 4 chemical drug, with certificate numbers 2025S01530 and 2025S01529 [1]. - The drug is approved for use in treating erectile dysfunction (ED) and was originally developed by Eli Lilly, receiving approvals in the EU and the US in 2002 and 2003, respectively, and in China in 2004 [1]. Market Context - The registration application for Tadalafil tablets was accepted on January 24, 2024, and the approval is valid until May 26, 2030 [1]. - Major competitors in the domestic market include Guangdong Dongyangguang Pharmaceutical Co., Ltd., Jiangsu Tianshili Diyi Pharmaceutical Co., Ltd., and Lefusi Health Industry Co., Ltd., with sales figures of RMB 185.73 million, RMB 1.294 billion, and RMB 1.61182 billion, respectively [1]. - The company has invested approximately RMB 2.5401 million and RMB 4.2976 million in the R&D of Tadalafil tablets (2.5mg and 5mg) [1]. Impact on the Company - The acquisition of the drug registration certificate will diversify the product range of the company's male medication offerings, thereby enhancing its competitiveness in the male medication market [2]. - The company plans to commence production in accordance with regulatory requirements and market demand [2].
白云山(600332) - 广州白云山医药集团股份有限公司关于分公司收到药品注册证书的公告

2025-06-06 09:00
证券代码:600332 证券简称:白云山 公告编号:2025-048 规格:2.5mg、5mg 注册分类:化学药品 4 类 证书编号:2025S01530、2025S01529 广州白云山医药集团股份有限公司 关于分公司收到药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏,并对其内容的真实性、准确性和完整性承担法律责任。 近日,广州白云山医药集团股份有限公司(以下简称"本公司") 分公司广州白云山医药集团股份有限公司白云山制药总厂(以下简称 "白云山制药总厂")收到国家药品监督管理局核准签发关于他达拉 非片(2.5mg、5mg)的《药品注册证书》。现将相关情况公告如下: 一、药品的基本情况 药品通用名称:他达拉非片 主要成份:他达拉非 剂型:片剂 药品注册标准编号:YBH10982025 上市许可持有人:(1)名称:广州白云山医药集团股份有限公 司白云山制药总厂;(2)地址:广州市白云区同和街云祥路 88 号 生产企业:(1)名称:广州白云山医药集团股份有限公司白云 山制药总厂;(2)地址:广州市白云区同和街云祥路 88 号 受理号:CYHS2400338、 ...
科技赋能传统 创新引领未来——白云山维一铁皮石斛益生菌荣获FFI2025"年度创新探索奖
Zhong Guo Chan Ye Jing Ji Xin Xi Wang· 2025-06-06 09:00
Core Insights - The health food industry is experiencing significant growth driven by innovation, with the FFI2025 Food Formula Innovation Forum highlighting future trends in functional foods [1] - Guangzhou Baiyunshan Weiyi Industrial Co., Ltd. showcased its star product, the Dendrobium officinale probiotic solid beverage, which won the "2025 Innovation Exploration Award" through expert evaluation and consumer voting [1][3] Group 1 - The Dendrobium officinale probiotic solid beverage combines traditional medicine and modern probiotic technology, meeting diverse health needs of modern consumers [3] - The expert panel praised the product for its innovative formula that integrates traditional wisdom with modern scientific logic, setting a benchmark in the probiotic market [3] Group 2 - Dendrobium officinale has a long history of medicinal use, documented in ancient texts like "Compendium of Materia Medica," and modern pharmacological studies confirm its health benefits due to over 30 active substances [5] - The company selected the AB21 composite probiotics, which include Lactobacillus plantarum and Lactococcus lactis, achieving a perfect blend of traditional medicine and modern probiotic technology [5] Group 3 - The forum reinforced the "scientific formula" concept of the Dendrobium officinale probiotics, reflecting the company's commitment to quality and consumer health, while promoting a healthy lifestyle [7] - As a key member of the Guangzhou Pharmaceutical Group's health industry, the company leverages its billion-level industrial ecosystem to meet consumer demands with a range of popular health products [7] - The company aims to continue its focus on "technology and traditional Chinese medicine," investing in the modernization and scientific research of traditional health culture to provide innovative and practical health solutions [7]